AR-A014418
IC50: 104 ± 27 nM
Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer’s disease (AD). AR-A014418 is a selective GSK-3 inhibitor.
In vitro: ARA014418 acted as an ATP-competitive manner and did not significantly inhibit cdk2 or cdk5 or 26 other kinases demonstrating high specificity for GSK3. AR-A014418 inhibited tau phosphorylation at a GSK3-specific site (Ser-396) in cells stably expressing human four-repeat tau protein [1].
In vivo: ARA014418 induced behavioural changes that were consistent with the effects of antidepressant drugs. Subacute intraperitoneal injections of AR-A014418 reduced immobility time in rats exposed to the forced swim test, which was a well-established model for antidepressant efficacy. Moreover, the specificity of this effect was supported by our finding that AR-A014418 decreased spontaneous as well as amphetamine-induced activity [2].
Clinical trial: currently no clinical data were available.
References:
[1] Bhat R, Xue Y, Berg S, Hellberg S, Orm M, Nilsson Y, Rades ter AC, Jerning E, Markgren PO, Borgeg rd T, Nyl f M, Giménez-Cassina A, Hernández F, Lucas JJ, Díaz-Nido J, Avila J.? Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem. 2003;278(46):45937-45.
[2] Gould TD, Einat H, Bhat R, Manji HK.? AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol. 2004;7(4):387-90.
- 1. Jing-Ting Chiou, Chia-Chi Hsu, et al. "Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells." Biochem Pharmacol. 2023 May:211:115494. PMID: 36924905
- 2. Sergey V. Rozhkov, Kristina A. Sharlo, et al. "The Role of Glycogen Synthase Kinase-3 in the Regulation of Ribosome Biogenesis in Rat Soleus Muscle under Disuse Conditions." Int J Mol Sci. 2022 Mar 2;23(5):2751. PMID:35269893
- 3. Jing‐Ting Chiou, Nan‐Chieh Huang, et al. "NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells." J Cell Physiol. 2021 Nov;236(11):7356-7375. PMID:33982799
- 4. Qiang Li, Dongmei Yu, et al. "TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signal-regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis." Transl Lung Cancer Res. 2021 Feb;10(2):936-954. PMID:33718034
- 5. Binyan Lin, Yongxu Li, et al. "CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK." Oncogene. 2020 Sep;39(37):6024-6040. PMID:32778769
- 6. Lee YC, Shi YJ, et al. "GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells." J Cell Physiol. 2020;10.1002/jcp.29884. PMID:32572959
- 7. Huang CH, Lee YC, et al. "Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells." Toxicol Appl Pharmacol. 2020;397:115013. PMID:32305283
- 8. Chen YJ, Huang CH, et al. "The suppressive effect of arsenic trioxide on TET2-FOXP3-Lyn-Akt axis-modulated MCL1 expression induces apoptosis in human leukemia cells." Toxicol Appl Pharmacol. 2018 Nov 1;358:43-55. PMID:30213730
- 9. Lee YC, Chen YJ, et al. "Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1." Apoptosis. 2016 Oct 19. PMID:27757735
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 308.31 |
Cas No. | 487021-52-3 |
Formula | C12H12N4O4S |
Synonyms | AR-AO 14418;AR 0133418;AR 014418;GSK 3β inhibitor |
Solubility | insoluble in EtOH; insoluble in H2O; ≥15.4 mg/mL in DMSO |
Chemical Name | 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea |
SDF | Download SDF |
Canonical SMILES | COC1=CC=C(C=C1)CNC(=O)NC2=NC=C(S2)[N+](=O)[O-] |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Kinase experiment [1]: | |
Kinase assays |
The competition experiments were carried out in duplicate with 10 concentrations of the inhibitor. The biotinylated peptide substrate was added at 2 μM in an assay buffer containing 6 milliunits of recombinant human GSK3, 12 mM MOPS, pH 7.0, 0.3 mM EDTA, 0.01% β-mercaptoethanol, 0.004% Brij 35, 0.5% glycerol, and 0.5 μg of bovine serum albumin/25 μl and preincubated. The reaction was initiated by the addition of 0.04 μCi of [-33P]ATP and unlabeled ATP in 50 mM Mg(Ac)2 to a final concentration of 1 μM ATP and assay volume of 25 μl. After incubation for 20 min at room temperature, each reaction was terminated by the addition of 25 μl of stop solution containing 5 mM EDTA, 50 μM ATP, 0.1% Triton X-100, and 0.25 mg of streptavidin-coated SPA beads corresponding to 35 pmol of binding capacity. |
Cell experiment [1]: | |
Cell lines |
3T3 fibroblasts were engineered to stably express four-repeat tau protein |
Preparation method |
The solubility of this compound in DMSO is >15.4 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
100 nM to 50 μM for 24 h |
Applications |
AR-A014418 could inhibit the tau phosphorylation at a GSK3-specific site in cells that were stably expressing human four-repeat tau protein. AR-A014418 could also protect N2A neuroblastoma cells against cell death, which was mediated through inhibition of the phosphatidylinositol 3-kinase/protein kinase B survival pathway. |
Animal experiment [2]: | |
Animal models |
Male Sprague–Dawley rats |
Dosage form |
30 μmol/kg, i.p. |
Application |
The subacute intraperitoneal injections of AR-A014418 reduced immobility time in rats exposed to the forced swim test, a well-established model for antidepressant efficacy. In addition, the specificity of this effect was supported by the finding that AR-A014418 could decrease both spontaneous and amphetamine-induced activity. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Bhat R, Xue Y, Berg S, Hellberg S, Orm M, Nilsson Y, Radester AC, Jerning E, Markgren PO, Borgegrd T, Nylf M, Giménez-Cassina A, Hernández F, Lucas JJ, Díaz-Nido J, Avila J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem. 2003;278(46):45937-45. [2] Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol. 2004;7(4):387-90. |
Description | AR-A014418 is an ATP-competitive, and selective inhibitor of GSK3β with IC50 and Ki of 104 nM and 38 nM | |||||
Targets | GSK-3 | |||||
IC50 | 104 +/- 27 nM |
Quality Control & MSDS
- View current batch: